You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Design and synthesis of bone-selective osteogenic oxysterol-bisphosphonate analog

    SBC: Max Biopharma, Inc.            Topic: NIAMS

    DESCRIPTION (provided by applicant): Osteoporosis affects 10 million Americans and another 34 million are osteopenic and at risk for developing osteoporosis. Bone fractures, the most important complication of osteoporosis, cause substantial morbidity andmortality in the aging population as well as significant socio-economic cost. Since the 1960's, bisphosphonate drug therapy has produced mod ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Novel Therapy for Tumor-induced Osteomalacia

    SBC: Panorama Research Incorporated            Topic: NIAMS

    DESCRIPTION (provided by applicant): Tumor-induced osteomalacia (TIO, or oncogenic osteomalacia) is an insidious, progressive, paraneoplastic disorder of abnormal phosphate and vitamin D metabolism caused by excessive fibroblast growth factor 23 (FGF23).Due to a lack of appreciation of the existence of this disease, as well as a typically slow onset of symptoms, the prevalence of TIO is most like ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Development of topical formulations for delivery of next generation mTOR inhibito

    SBC: TRANSDERM, INC.            Topic: NIAMS

    DESCRIPTION (provided by applicant): We discovered that the inducible keratins 6a and 6b, mutations in which can result in the skin and nail disorder pachyonychia congenita (PC), contain regulatory motifs in their 5'-untranslated regions that make them susceptible to mTOR inhibitors, including rapamycin. Using RNA profiling and immunohistochemistry of foot sole biopsies taken from PC lesions ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Multiplexed Assays for Improving Rheumatoid Arthritis Diagnostics

    SBC: PROGNOSYS BIOSCIENCES, INC.            Topic: NIAMS

    DESCRIPTION (provided by applicant): There is a need for multiplexed assay technologies that enable diagnostics and detailed characterization of rheumatoid arthritis. In this project we plan to discover new rheumatoid arthritis biomarkers and implement them in a panel of multiplexed assays. We propose a novel approach that offers significant advances over existing methods, including the ability to ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Detection of Botanicals and Adulterants Using the Novel DNA-Based Technology Seq

    SBC: AUTHENTECHNOLOGIES, LLC            Topic: NCCIH

    DESCRIPTION (provided by applicant): From cosmetics, to supplements and pharmaceuticals- natural products using a wide-array of botanicals play an important role in our health and wellbeing. However, deceitful adulteration poses a great risk to the naturalproducts industry and the safety of its consumers; there are a number of well-known cases involving substitution by toxic species that have led ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Ultrahigh-throughput Identification of Molecular Targets of Natural Products

    SBC: NEWOMICS INC.            Topic: NCCIH

    DESCRIPTION (provided by applicant): Natural products are rich sources for potential drugs. To accelerate drug discovery from natural products, it is imperative to identify their molecular targets, and mechanistically elucidate their bioavailability, toxicity, and therapeutic effects. However, there remain several challenges in the field. Among them, there is currently no technical platform that c ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Methods for improving the properties of antibody-drug conjugates

    SBC: IGENICA, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Antibody drug conjugates (ADCs), a rapidly growing class of targeted therapeutics, represent a promising new approach toward improving both the selectivity and the cytotoxic activity of cancer drugs. Although several ADCs have demonstrated recent clinical success, the utility of most ADCs currently in development is limited by cumbersome synthetic processes, in ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Direct RT-qPCR analysis of microRNAs in human plasma (miR-Direct)

    SBC: Somagenics, Inc.            Topic: NCI

    Our goal in this proposal is to develop a novel method for the direct detection of miRNAs in serum and plasma without requiring isolation of total RNA. Distinct expression profiles of microRNAs (miRNAs) have recently been associated with cancer and other diseases, implying that miRNAs could serve as diagnostic biomarkers for these diseases. Effective biomarkers could facilitate early detection of ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Engineering of human H-NOX as an oxygen delivery therapeutic for prolonged admini

    SBC: OMNIOX INC            Topic: NCI

    Engineering'of'Human'H.NOX'as'an'Oxygen'Delivery'Therapeutic'for'Prolonged'Administration' ' ' Project Summary/Abstract Omniox has developed a class of tunable oxygen-delivery agents that significantly alleviate tumor hypoxia to enhance the efficacy of radiotherapy (RT). This family of therapeutic proteins, called H-NOX, can oxy ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Intraoperative assessment of non-melanoma skin cancer margins using NIRF probes.

    SBC: Akrotome Imaging, INC            Topic: NCI

    DESCRIPTION (provided by applicant): The incidence of skin cancer is increasing rapidly in the US. In 1994, there were around 1 million cases of non-melanoma skin cancer per year; this number had grown to more than 4 million by 2011. Many of these tumorsappear in areas of the body that are exposed to sunlight (face, hands, etc.), where cosmetic considerations require minimizing resection of norma ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government